✦ LIBER ✦

6514 ORAL Adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study evaluating the MAGE-A3 cancer immunotherapeutic

✍ Scribed by Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabre, J.; Esteban, E.; Malinowski, W.; Jassem, J.; Passlick, B.; López-Brea, M.; Vanakesa, T.

Book ID: 123318788
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 59 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(07)71342-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

MAGE-A3 Antigen-Specific Cancer Immunoth

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC): from proof-of-concept to phase III trial (MAGRIT)

✍ Eisen, T.; Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabreh, J.; Jassem, J 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

102PD MAGE-A3 ANTIGEN-SPECIFIC CANCER IM

102PD MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC): FROM PROOF-OF-CONCEPT TO PHASE III TRIAL (MAGRIT)

✍ Passlick, B.; Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabreh, J.; Esteba 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 44 KB

P-554 Randomized Phase II study of first

P-554 Randomized Phase II study of first-line docetaxel (D)/ gemcitabine (G) doublet chemotherapy versus fixed duration (3 cycles) sequential single agent chemotherapy (D then G) in Stage IIIB/IV non-small cell lung cancer (NSCLC)—Final Results. A study by the NSW and Australian Lung Cancer Trials Group

✍ Pavlakis, N.; McCowatt, S.; Lewis, C.; Marx, G.; Abell, F.; Della-Fiorentina, S. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 144 KB